634 jobs. That’s Takeda’s WARN-noticed US headcount cut, and the geography tells the real story.
The restructuring lands hardest on Cambridge, Massachusetts — Takeda’s US headquarters. 247 of the 634 cuts are concentrated there, making it the single largest hit in the filing. That’s almost 40% of the total in one zip code. The remaining roles are spread across other US locations the company didn’t itemize in the notice.
The context matters. Cambridge has been Big Pharma’s preferred US address for over a decade. Takeda, Sanofi, Novartis, and a long list of other multinationals built or expanded their US R&D and commercial operations there to be close to MIT, Harvard, and the broader Boston biotech ecosystem. The talent gravity made Cambridge expensive — and now, when restructuring hits, expensive is the first thing to go.
There’s a political layer too. Trump’s 100% pharma tariff regime, announced last week, gave companies an explicit incentive to commit US manufacturing investment in exchange for exemptions. Thirteen drugmakers signed up. Takeda was one of the names on that list. Investment commitments are a press-release item. They don’t translate one-to-one into jobs in the same old buildings.
The 634-cut notice doesn’t itemize which functions get hit hardest. Past restructurings at Takeda have favored cuts to commercial and support functions while protecting late-stage R&D — so the Cambridge mix likely skews toward MSL, marketing, and back-office roles, not lab seats.
Restructuring rolls into Q3.
— Diana Kowalski